Once-Weekly Semaglutide in Adults with Overweight or Obesity.
High Confidence RCTPrimary source: [Open]
Linked compounds: semaglutide
Outcomes summary
Randomized, placebo-controlled trial evaluating once-weekly semaglutide 2.4 mg plus lifestyle intervention in adults with overweight/obesity; semaglutide produced substantially greater weight loss than placebo, with gastrointestinal adverse events common.
Limitations
Industry-sponsored; outcomes depend on adherence and concomitant lifestyle intervention; discontinuations and missing data handling affect estimates.
Notes
Primary source: PMID 33567185 (see PubMed link on this page).